strontium/stroke

Lyen an sove nan clipboard la

AtikEsè klinikPatant

Chwazi kalite sòt

15 rezilta yo

New strategies for osteoporosis patients previously managed with strontium ranelate.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The aim of this article is to describe potential alternatives to patients no longer eligible for management with strontium ranelate for osteoporosis according to the recommendations by the European Medicines Agency. A systematic search of Pubmed was done for papers on fracture efficacy of various

Stroke in relation to use of raloxifene and other drugs against osteoporosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Prior studies have associated fatal stroke with raloxifene. In a cohort study, we found no excess risk of stroke with raloxifene; whereas, an excess risk of stroke and fatal stroke was seen with alendronate and etidronate. However, the excess risks were small. OBJECTIVE We aim to study the

Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

National registers showed that a large proportion of patients treated with strontium ranelate have conditions that may now contraindicate use. The risk of death in strontium ranelate-treated patients was significantly higher than that seen in users of other osteoporosis drugs even after adjusting

[Osteoporosis treatment].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

As for any chronic disease, adherence to osteoporosis treatment is low. Folates and vitamin B12 decrease hip fracture risk in elderly Japanese with stroke. Raloxifene (Evista) decreases the incidence of positive estrogen receptor breast cancer and could prevent cardiovascular events in patients at

Influence of desensitizing and anti-erosive toothpastes on dentine permeability: An in vitro study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This study analyzed the effect of desensitizing and/or anti-erosive toothpastes on dentine permeability.One-mm dentin discs were prepared from human molars and exposed to EDTA solution (5 min, 17%). Initial dentine permeability was measured, under constant

[Osteoporosis treatment].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The diagnosis threshold of osteoporosis is based on low bone density value. The therapeutic threshold is modulated by clinical risk factors. Denosumad, an antibody raised against RANK-Ligand, is a potent bone resorption inhibitor. Efficacy on the reduction of fracture incidence is well documented

New findings with old drugs for osteoporosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Postmenopausal osteoporosis is common and is associated with stooped posture, loss of height, back pain and fractures. OBJECTIVE This evaluation is of clinical outcome trials with tibolone (Long-Term Intervention of Fractures with Tibolone) and strontium ranelate (Spinal Osteoporosis

Efficacy of a desensitizing toothpaste containing arginine and calcium carbonate on dentin surface pore structure and dentin morphology.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To investigate the laboratory changes in dentin tubule occlusion morphology during short term use of desensitizing products as evaluated by electron microscopy and an image analysis. METHODS Freshly extracted human third molar teeth were collected at random and 40 dentin discs were

Lidocaine-induced reduction in size of experimental myocardial infarction.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In anesthetized open chest dogs, the effects of therapeutic doses of lidocaine on myocardial cell respiration, creatine kinase depletion, left ventricular stroke work and cardiac necrosis were assessed. The dogs were subjected to 40 minutes of occlusion of the left anterior descending coronary

How to manage postmenopausal osteoporosis?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased fracture risk. Several therapeutic agents are now available to treat postmenopausal osteoporosis and prevent fractures. Combined calcium and vitamin D supplementation reduce the relative

Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In this review, benefits and side-effects of current and emerging therapies to treat and prevent pathological bone loss are described. Bisphosphonates are the antiresorptive compounds most widely used in the treatment of bone-loss associated diseases. They are generally well-tolerated although have

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The pharmacological management of disease should involve consideration of the balance between the beneficial effects of treatment on outcome and the probability of adverse effects. The aim of this review is to explore the risk of adverse drug reactions and drug-drug interactions with treatments for

Effect of dentinal tubule occlusion by dentifrice containing nano-carbonate apatite.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This study evaluated the effects of the short-term use of a dentifrice containing nano-sized carbonate apatite (n-CAP) on the occlusion of the dentinal tubules using a scanning electron microscope (SEM) and an image analyser in vitro. One hundred human dentine specimens were wet ground with a

Safety of drugs used in the treatment of osteoporosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A number of drug classes are licensed for the treatment of osteoporosis including bisphosphonates, recombinant human parathyroid hormone (PTH), strontium, hormone replacement therapy (HRT), selective oestrogen receptor modulators (SERMS) and denosumab. This review discusses the safety of

Adverse drug reactions to osteoporosis treatments.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Treatments for postmenopausal osteoporosis are generally safe, but are linked to some rare serious adverse drug reactions, for which causality is not always certain. The bisphosphonates are associated with gastrointestinal effects, acute phase reactions, and musculoskeletal pain, and, more rarely,

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye